A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade (KLG) 2 or 3 Osteoarthritis of the Knee

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade (KLG) 2 or 3 Osteoarthritis of the Knee

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Tonogenchoncel-L (Primary)
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors TissueGene
  • Most Recent Events

    • 26 Jun 2017 Status changed from planning to not yet recruiting.
    • 01 Nov 2016 According to a TissueGene media release, received a Special Protocol Assessment designation for this trial. Company anticipated to initiate this trial in the second quarter of 2017.
    • 15 May 2015 According to a TissueGene media release, it has reached an agreement with the US Food and Drug Administration regarding Special Protocol Assessment (SPA) for this trial. As per SPA, data from the trial will be used as the basis for submission of a Biologics License Application.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top